Vault-13

Lynx1 Capital Management LP

DORADO, PR · CIK 1910456 · 13F filing filed 2023-08-14

SEC-registered investment adviser since 2023 · limited partnership

As an employer

$152.6m reported value +27.2% vs Q1 2023
18positions
96.1%in top 10
6 new 4 added 7 reduced 1 sold out vs Q1 2023

This report includes the holdings of 1 other manager that shares the investment decisions:

Shares in two reports are counted once in each security's totals.

Holdings, Q2 2023

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 MERUS N V COM MRUS MRUS 1,152,525 $30.3m19.88% 19.88% AddedShares held: Q3 2022 613.1k, Q4 2022 854.6k, Q1 2023 1.1m, Q2 2023 1.2m +84.8k +84,802 7.9%
2 CABALETTA BIO INC COM CABA CABA 2,181,377 $28.2m18.45% 18.45% ReducedShares held: Q3 2022 0, Q4 2022 2.8m, Q1 2023 2.5m, Q2 2023 2.2m -273.2k -273,250 -11.1%
3 ALPINE IMMUNE SCIENCES INC COM NVLS NVLS 2,670,472 $27.5m17.99% 17.99% ReducedShares held: Q3 2022 3.1m, Q4 2022 3.1m, Q1 2023 3.1m, Q2 2023 2.7m -465.7k -465,701 -14.8%
4 CYMABAY THERAPEUTICS INC COM CBAY CBAY 1,205,050 $13.2m8.65% 8.65% ReducedShares held: Q3 2022 2.3m, Q4 2022 1.7m, Q1 2023 1.4m, Q2 2023 1.2m -164.9k -164,877 -12.0%
5 TSCAN THERAPEUTICS INC COM TCRX TCRX 5,224,600 $13.1m8.56% 8.56% NewShares held: Q3 2022 0, Q4 2022 0, Q1 2023 0, Q2 2023 5.2m
6 GH RESEARCH PLC ORDINARY SHARES GHRS GHRS 969,374 $11.5m7.54% 7.54% NewShares held: Q3 2022 0, Q4 2022 0, Q1 2023 0, Q2 2023 969.4k
7 PARDES BIOSCIENCES INC COM COM 3,902,434 $7.1m4.63% 4.63% AddedShares held: Q3 2022 2.3m, Q4 2022 3.0m, Q1 2023 3.3m, Q2 2023 3.9m +578.4k +578,373 17.4%
8 THESEUS PHARMACEUTICALS INC COM COM 757,009 $7.1m4.63% 4.63% ReducedShares held: Q3 2022 504.9k, Q4 2022 784.2k, Q1 2023 761.3k, Q2 2023 757.0k -4.2k -4,249 -0.6%
9 KINNATE BIOPHARMA INC COM KNTE KNTE 2,048,736 $6.2m4.07% 4.07% ReducedShares held: Q3 2022 1.7m, Q4 2022 2.0m, Q1 2023 2.2m, Q2 2023 2.0m -165.5k -165,514 -7.5%
10 NEOLEUKIN THERAPEUTICS INC COM COM 3,094,554 $2.6m1.68% 1.68% AddedShares held: Q3 2022 0, Q4 2022 2.3m, Q1 2023 2.4m, Q2 2023 3.1m +666.2k +666,231 27.4%
11 PIERIS PHARMACEUTICALS INC COM COM 9,775,849 $1.6m1.06% 1.06% AddedShares held: Q3 2022 3.5m, Q4 2022 5.6m, Q1 2023 7.1m, Q2 2023 9.8m +2.7m +2,708,131 38.3%
12 CULLINAN THERAPEUTICS INC COM CGEM CGEM 115,063 $1.2m0.81% 0.81% NewShares held: Q3 2022 0, Q4 2022 0, Q1 2023 0, Q2 2023 115.1k
13 PASSAGE BIO INC COM COM 1,167,343 $1.1m0.72% 0.72% ReducedShares held: Q3 2022 2.8m, Q4 2022 3.4m, Q1 2023 3.4m, Q2 2023 1.2m -2.2m -2,240,255 -65.7%
14 STRUCTURE THERAPEUTICS INC SPONSORED ADS GPCR GPCR 23,000 $956.1k0.63% 0.63% UnchangedShares held: Q3 2022 0, Q4 2022 0, Q1 2023 23.0k, Q2 2023 23.0k
15 ATHIRA PHARMA INC COM COM 193,573 $571.0k0.37% 0.37% NewShares held: Q3 2022 0, Q4 2022 0, Q1 2023 0, Q2 2023 193.6k
16 PHARVARIS N V COM PHVS PHVS 21,225 $321.3k0.21% 0.21% ReducedShares held: Q3 2022 0, Q4 2022 25.3k, Q1 2023 26.2k, Q2 2023 21.2k -5.0k -5,000 -19.1%
17 COMPASS PATHWAYS PLC SPONSORED ADS CMPS CMPS 20,114 $166.5k0.11% 0.11% NewShares held: Q3 2022 0, Q4 2022 0, Q1 2023 0, Q2 2023 20.1k
18 DBV TECHNOLOGIES S A SPONSORED ADR SPONSORED ADR 18,265 $34.7k0.02% 0.02% NewShares held: Q3 2022 0, Q4 2022 0, Q1 2023 0, Q2 2023 18.3k

Sold out since Q1 2023

SecurityTickerShares held beforeValue then
BELLUS HEALTH INC NEW BLU BLU 866,646 $6.2m866.6k shares

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

CompanyTickerStakeChange ScheduleLast filed
PASSAGE BIO INC 13D · filed 2026-07-02 21.0% +1.4 pts 13D 2026-07-02
GH RESEARCH PLC GHRS · 13G · filed 2026-08-14 GHRS 19.3%≈ $354.0m +1.9 pts 13G 2026-08-14
NEUPHORIA THERAPEUTICS INC NEUP · 13D · filed 2025-12-29 NEUP 16.3%≈ $3.8m no change 13D 2025-12-29
TSCAN THERAPEUTICS INC TCRX · 13G · filed 2026-08-14 TCRX 13.1%≈ $20.1m -1.9 pts 13G 2026-08-14
KORRO BIO INC KRRO · 13G · filed 2026-04-02 KRRO 10.7%≈ $20.3m +2.9 pts 13G 2026-04-02
C4 THERAPEUTICS INC CCCC · 13G · filed 2026-08-14 CCCC 10.0%≈ $63.1m +2.7 pts 13G 2026-08-14
CULLINAN THERAPEUTICS INC CGEM · 13G · filed 2025-11-14 CGEM 9.8%≈ $105.0m -4.7 pts 13G 2025-11-14
STOKE THERAPEUTICS INC STOK · 13G · filed 2026-08-14 STOK 6.5%≈ $132.1m -1.6 pts 13G 2026-08-14
IBIO INC IBIO · 13G · filed 2026-08-14 IBIO 5.4%≈ $4.9m +5.4 pts 13G 2026-08-14
PRECISION BIOSCIENCES INC DTIL · 13G · filed 2026-07-20 DTIL 5.4%≈ $10.9m +1.3 pts 13G 2026-07-20
AGIOS PHARMACEUTICALS INC AGIO · 13G · filed 2026-05-06 AGIO 5.1%≈ $111.8m new 13G 2026-05-06

Trades reported as a company insider in Q2 2023

Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.

DateCompanyTickerTradeShares ValueTheir holding
2023-05-31 TSCAN THERAPEUTICS INC 10% owner · See footnote TCRX Sold 25,400 $63.9k25.4k shares -0%